Skip to main content

Table 5 Acute and late toxicities in the propensity-matched cohorts [n (%)]

From: Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas

Toxicities P67.5 P70 P*
Grade 0 Grade 1-2 Grade 3-4 Grade 0 Grade 1-2 Grade 3-4
Acute toxicities        
 Skin reaction 5 (3.4%) 137 (92.5%) 6 (4.1%) 5 (3.4%) 136 (91.9%) 7 (4.7%) 0.961
 Mucositis 2 (1.4%) 133 (89.8%) 13 (8.8%) 1 (0.7%) 141 (95.2%) 6 (4.1%) 0.207
 Xerostomia 2 (1.4%) 146 (98.6%) 0 7 (4.7%) 141 (95.3%) 0 0.091
 Pharyngo-esophagitis 0 144 (97.3%) 4 (2.7%) 4 (2.7%) 143 (96.6%) 1 (0.7%) 0.055
 Leucopenia 31 (20.9%) 79 (53.4%) 38 (25.7%) 58 (39.2%) 80 (54.0%) 10 (6.8%) 0.000
 Anemia 73 (49.3%) 71 (48.0%) 4 (2.7%) 137 (92.6%) 11 (7.4%) 0 0.000
 Thrombocytopenia 118 (79.7%) 23 (15.6%) 7 (4.7%) 140 (94.6%) 8 (5.4%) 0 0.000
 Weight loss <5%
13 (8.8%)
5%-10%
39 (26.3%)
≥10%
96 (64.9%)
<5%
16 (10.8%)
5%-10%
47 (31.7%)
≥10%
85 (57.5%)
0.423
Late toxicities Grade 0 Grade 1 Grade 2+ Grade 0 Grade 1 Grade 2+  
 Subcutaneous fibrosis 92 (62.2%) 53 (35.8%) 3 (2.0%) 87 (58.8%) 51 (34.5%) 10 (6.7%) 0.139
 Xerostomia 29 (19.6%) 111 (75.0%) 8 (5.4%) 19 (12.8%) 122 (82.4%) 7 (4.7%) 0.263
 Otitis media 116 (78.4%) 32 (21.6%) 0 116 (78.4%) 31 (20.9%) 1 (0.7%) 0.602
 Taste changes 106 (71.6%) 41 (27.7%) 1 (0.7%) 120 (81.1%) 25 (16.9%) 3 (2.0%) 0.057
 Dehisce difficulty 122 (82.4%) 25 (16.9%) 1 (0.7%) 132 (89.2%) 16 (10.8%) 1 (0.7%) 0.306
 Hearing loss 75 (50.7%) 60 (40.5%) 13 (8.8%) 80 (54.1%) 59 (39.9%) 9 (6.1%) 0.639
 Tooth and periodontal diseases 86 (58.1%) 56 (37.8%) 6 (4.1%) 80 (54.1%) 52 (35.1%) 16 (10.8%) 0.086
 Hypothyroidism 143 (96.6%) 4 (2.7%) 1 (0.7%) 138 (93.2%) 8 (5.4%) 2 (1.4%) 0.416
  1. *P-values were calculated using the Pearson χ2 test